Exhibit 10.4
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.
SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS
ITEM | SUPPLIES/SERVICES | QTY/UNIT | UNIT PRICE | EXTENDED PRICE |
0002-02 | BioThrax [**] product BioThrax [**] product [**] upon date of delivery [**] Corresponds to Line Item 0002B in contract. To be delivered in accordance with the delivery schedule below | [**] Doses | $[**] | $[**] |
Line(s) Of Accounting: 939ZTGA 2642 2012 75-X-0956 5664711101 $[**] |
Option 1 Option for Additional Items:
ITEM | SUPPLIES/SERVICES | QTY/UNIT | UNIT PRICE | EXTENDED PRICE |
0002-02 | BioThrax [**] product BioThrax [**] product [**] upon date of delivery [**] To be delivered in accordance with the delivery schedule below | [**] Doses | $[**] | $[**] |
Line(s) Of Accounting: 939ZTGA 2642 2012 75-X-0956 5664711101 [**] |
The purpose of this modification is to transfer funds between CLINS, modify the product doses as described and incorporate these in scope changes to contract #200-2011-42084.
A. | The contract funded amount for CLIN 0002 is decreased by $[**] from $[**] to $[**]. CLIN0002 is reduced in quantity from [**] product doses to [**] product doses. |
As a result:
1. | CLIN 0002- 02 is is funded in the amount of $[**] for [**] product doses. |
2. | Section C.2 Delivery Schedule and section F.3.1 are revised as follows: |
Product | ||||
CLIN | Price per Dose | Doses | $ | Delivery Period |
0001 | [**] | [**] | [**] | October 1, 2011 to December 31, 2012 |
0002 | [**] | [**] | [**] | January 1, 2013 to November 30, 2013 |
0002-02 | [**] | [**] | [**] | January 1, 2013 to November 30, 2014 |
0003 | [**] | [**] | [**] | December 1, 2013 to November 30, 2014 |
0004 | [**] | [**] | [**] | December 1, 2014 to October 31, 2015 |
0005 | [**] | [**] | [**] | November 1, 2015 to September 30, 2016 |
Total | 44,750,000 | $1,234,775,641.30 |
Consider all other terms and conditions of the contract unchanged and in full force and effect.